Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Neurizon Therapeutics.
RELATED STOCKHEAD STORIES
Health & Biotech
Health Check: Brokers slash Cochlear valuations as customers hold tight on product upgrades
Health & Biotech
Rare opportunities – ASX health stocks tackling unmet medical needs
News
Closing Bell: ASX climbs as miners flex; US SEC eases up on crypto crackdown
Health & Biotech
Neurizon granted US patent for lead drug to treat motor neurone and other neurodegenerative conditions
Health & Biotech
Health Kick Podcast: Neurizon gears up for big year in tackling ALS
Health & Biotech
Stocking stuffers: Morgans’ top ASX health picks for 2025
Health & Biotech
Scott Power: Which stock fell off its perch on poor trial results this week?
Health & Biotech
In big news week Neurizon secures key orphan status for motor neurone drug in Europe
Health & Biotech
Neurizon files key IND application with US FDA for motor neurone disease drug
Health & Biotech
Health Check: It’s a wipe out! Percheron shares tumble up to 91pc on rare genetic disease trial failure
Health & Biotech
Positive interim study results for Neurizon’s motor neurone disease drug
Health & Biotech
Health Check: Can Syntara produce the next multibillion-dollar Aussie blood cancer drug?
Health & Biotech
Preclinical studies confirm potential of Neurizon’s lead drug to treat ALS
Health & Biotech
Scott Power: S&P/ASX 200 Health Care Index falls but which stocks are up on positive news?
Health & Biotech
NUZ inks positive opinion on orphan product designation for NUZ-001 in Europe
Health & Biotech
Spark Plus sees 225pc upside in biotech player Neurizon
Health & Biotech
